Literature DB >> 24398389

Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers.

Courtney Schaal1, Srikumar P Chellappan.   

Abstract

Tobacco smoke contains multiple classes of established carcinogens including benzo(a)pyrenes, polycyclic aromatic hydrocarbons, and tobacco-specific nitrosamines. Most of these compounds exert their genotoxic effects by forming DNA adducts and generation of reactive oxygen species, causing mutations in vital genes such as K-Ras and p53. In addition, tobacco-specific nitrosamines can activate nicotinic acetylcholine receptors (nAChR) and to a certain extent β-adrenergic receptors (β-AR), promoting cell proliferation. Furthermore, it has been demonstrated that nicotine, the major addictive component of tobacco smoke, can induce cell-cycle progression, angiogenesis, and metastasis of lung and pancreatic cancers. These effects occur mainly through the α7-nAChRs, with possible contribution from the β-ARs and/or epidermal growth factor receptors. This review article will discuss the molecular mechanisms by which nicotine and its oncogenic derivatives such as 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N-nitrosonornicotine induce cell-cycle progression and promote tumor growth. A variety of signaling cascades are induced by nicotine through nAChRs, including the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway, phosphoinositide 3-kinase/AKT pathway, and janus-activated kinase/STAT signaling. In addition, studies have shown that nAChR activation induces Src kinase in a β-arrestin-1-dependent manner, leading to the inactivation of Rb protein and resulting in the expression of E2F1-regulated proliferative genes. Such nAChR-mediated signaling events enhance the proliferation of cells and render them resistant to apoptosis induced by various agents. These observations highlight the role of nAChRs in promoting the growth and metastasis of tumors and raise the possibility of targeting them for cancer therapy. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24398389      PMCID: PMC3915512          DOI: 10.1158/1541-7786.MCR-13-0541

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  91 in total

1.  Mechanisms of mitogen-activated protein kinase activation by nicotine in small-cell lung carcinoma cells.

Authors:  M G Cattaneo; F D'atri; L M Vicentini
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

2.  Nicotinic modulation of therapeutic response in vitro and in vivo.

Authors:  Graham W Warren; Michelle A Romano; Mahesh R Kudrimoti; Marcus E Randall; Ronald C McGarry; Anurag K Singh; Vivek M Rangnekar
Journal:  Int J Cancer       Date:  2012-04-16       Impact factor: 7.396

Review 3.  Genetic alterations defining NSCLC subtypes and their therapeutic implications.

Authors:  Larissa A Pikor; Varune R Ramnarine; Stephen Lam; Wan L Lam
Journal:  Lung Cancer       Date:  2013-08-20       Impact factor: 5.705

4.  Lung cancer incidence in never smokers.

Authors:  Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West
Journal:  J Clin Oncol       Date:  2007-02-10       Impact factor: 44.544

5.  Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.

Authors:  José G Treviño; Monika Verma; Sandeep Singh; Smitha Pillai; Dongyu Zhang; Daniele Pernazza; Said M Sebti; Nicholas J Lawrence; Barbara A Centeno; Srikumar P Chellappan
Journal:  Mol Cancer Ther       Date:  2013-10-09       Impact factor: 6.261

6.  Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo.

Authors:  Kip A West; Ilona R Linnoila; Steven A Belinsky; Curtis C Harris; Phillip A Dennis
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

Review 7.  Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases.

Authors:  Richard D Egleton; Kathleen C Brown; Piyali Dasgupta
Journal:  Pharmacol Ther       Date:  2008-11-14       Impact factor: 12.310

8.  Relation of nicotine yield of cigarettes to blood nicotine concentrations in smokers.

Authors:  M A Russell; M Jarvis; R Iyer; C Feyerabend
Journal:  Br Med J       Date:  1980-04-05

9.  Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells.

Authors:  Rong-Jane Chen; Yuan-Soon Ho; How-Ran Guo; Ying-Jan Wang
Journal:  Toxicol Sci       Date:  2010-01-27       Impact factor: 4.849

10.  Nicotine overrides DNA damage-induced G1/S restriction in lung cells.

Authors:  Takashi Nishioka; Daisuke Yamamoto; Tongbo Zhu; Jinjin Guo; Sung-Hoon Kim; Chang Yan Chen
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

View more
  117 in total

Review 1.  Activation of the Macrophage α7 Nicotinic Acetylcholine Receptor and Control of Inflammation.

Authors:  Carlos A Báez-Pagán; Manuel Delgado-Vélez; José A Lasalde-Dominicci
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-14       Impact factor: 4.147

Review 2.  Comprehensive review of epidemiological and animal studies on the potential carcinogenic effects of nicotine per se.

Authors:  Hans-Juergen Haussmann; Marc W Fariss
Journal:  Crit Rev Toxicol       Date:  2016-06-09       Impact factor: 5.635

3.  Nicotine upregulates microRNA-21 and promotes TGF-β-dependent epithelial-mesenchymal transition of esophageal cancer cells.

Authors:  Yi Zhang; Tiecheng Pan; Xiaoxuan Zhong; Cai Cheng
Journal:  Tumour Biol       Date:  2014-04-23

Review 4.  The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support.

Authors:  Graham W Warren; Samantha Sobus; Ellen R Gritz
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

5.  Key residues in the nicotinic acetylcholine receptor β2 subunit contribute to α-conotoxin LvIA binding.

Authors:  Dongting Zhangsun; Xiaopeng Zhu; Yong Wu; Yuanyan Hu; Quentin Kaas; David J Craik; J Michael McIntosh; Sulan Luo
Journal:  J Biol Chem       Date:  2015-02-20       Impact factor: 5.157

Review 6.  Proteins and chemical chaperones involved in neuronal nicotinic receptor expression and function: an update.

Authors:  Arianna Crespi; Sara Francesca Colombo; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2017-04-19       Impact factor: 8.739

Review 7.  E-cigarettes/electronic nicotine delivery systems: a word of caution on health and new product development.

Authors:  Michael Unger; Darian W Unger
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

8.  Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer.

Authors:  Supriya Srinivasan; Tulasigeri Totiger; Chanjuan Shi; Jason Castellanos; Purushottam Lamichhane; Austin R Dosch; Fanuel Messaggio; Nilesh Kashikar; Kumaraswamy Honnenahally; Yuguang Ban; Nipun B Merchant; Michael VanSaun; Nagaraj S Nagathihalli
Journal:  Cancer Res       Date:  2018-09-19       Impact factor: 12.701

9.  α9- and α7-containing receptors mediate the pro-proliferative effects of nicotine in the A549 adenocarcinoma cell line.

Authors:  Vanessa Mucchietto; Francesca Fasoli; Susanna Pucci; Milena Moretti; Roberta Benfante; Annalisa Maroli; Simona Di Lascio; Cristiano Bolchi; Marco Pallavicini; Cheryl Dowell; Michael McIntosh; Francesco Clementi; Cecilia Gotti
Journal:  Br J Pharmacol       Date:  2017-09-08       Impact factor: 8.739

10.  Impact of smoking on multiple primary cancers survival: a retrospective analysis.

Authors:  A Romaszko-Wojtowicz; A Buciński; A Doboszyńska
Journal:  Clin Exp Med       Date:  2018-03-17       Impact factor: 3.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.